Save time and jump to the most important pieces.
Vancouver, British Columbia--(Newsfile Corp. - September 6, 2022) - Burcon NutraScience Corporation (TSX:BU) (NASDAQ:BRCN) ("Burcon" or the "Company"), a global technology leader in the development of plant-based proteins for foods and beverages, today issued a letter to shareholders from its Interim CEO and Chairman of the Board, Peter H. Kappel.Dear Fellow Shareholders,This past Friday we announced the resignation of our Auditor of the past 21 years, PricewaterhouseCoopers LLP ("PwC"). This must have come as a surprise to you, as it did us when we were informed by PwC their intention to resign. What was particularly agonizing for us was their insistence on the immediacy of carrying throu
Vancouver, British Columbia--(Newsfile Corp. - September 2, 2022) - Burcon NutraScience Corporation (TSX:BU) (NASDAQ:BRCN) ("Burcon" or the "Company"), a global technology leader in the development of plant-based proteins for foods and beverages, today announced that it intends to file a Form 25 (Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934) with the Securities and Exchange Commission (the "SEC") on September 12, 2022 to delist the Company's common shares from the Nasdaq Capital Market and to deregister its common shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The comm
Vancouver, British Columbia--(Newsfile Corp. - September 2, 2022) - Burcon NutraScience Corporation (TSX:BU) (NASDAQ:BRCN) ("Burcon" or the "Company"), a global technology leader in the development of plant-based proteins for foods and beverages, today announced the resignation of its auditors, PricewaterhouseCoopers LLP ("PwC"), effective September 1, 2022 and that it is postponing its annual meeting of shareholders (the "AGM"), which was to be held on September 14, 2022.PwC has confirmed that there have been no "reportable events", "disagreements" or "unresolved issues" (as such terms are defined in National Instrument 51-102 - Continuous Disclosure Obligations). Due to the inopportune tim
6-K - Burcon NutraScience Corp (0001158399) (Filer)
D - Burcon NutraScience Corp (0001158399) (Filer)
25 - Burcon NutraScience Corp (0001158399) (Filer)
SC 13G - Burcon NutraScience Corp (0001158399) (Subject)
SC 13G - Burcon NutraScience Corp (0001158399) (Subject)
Vancouver, British Columbia--(Newsfile Corp. - August 15, 2022) - Burcon NutraScience Corporation (TSX:BU) (NASDAQ:BRCN) ("Burcon or the "Company"), a global technology leader in the development of plant-based proteins for foods and beverages, reported results for the fiscal first quarter ended June 30, 2022.Operational highlights for the first quarter ended June 30, 2022:During the quarter, Burcon:recorded a 17% quarter-over-quarter increase in royalty revenues from its licensee, Merit Functional Foods Corporation ("Merit");provided a $3.16 million loan to Merit, as part of a $10 million funding contributed by shareholders in proportion to their Merit shareholding;advanced the due diligence
Vancouver, British Columbia--(Newsfile Corp. - August 2, 2022) - Burcon NutraScience Corporation (TSX:BU) (NASDAQ:BRCN) ("Burcon" or the "Company"), a global technology leader in the development of plant-based proteins for foods and beverages, will hold an investor conference call and webcast on Monday, August 15, 2022 at 5:00 p.m. Eastern time to discuss its financial results for the fiscal first quarter ended June 30, 2022. The Company's financial results will be issued in a press release prior to the call.A link to the webcast of the conference call will be available on Burcon's website under "Presentations" or directly here. The webcast will also be archived for future playback.Investo
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2022) - Burcon NutraScience Corporation (TSX:BU) (NASDAQ:BRCN) ("Burcon or the "Company"), a global technology leader in the development of plant-based proteins for foods and beverages, reported results for the fiscal year ended March 31, 2022."Fiscal 2022 was a year in which we saw the successful commercialization of Burcon's pea and canola protein technologies, establishing our joint venture and licensee, Merit Functional Foods, as the world's first and only commercial producer of food-grade canola protein ingredients," said Peter H. Kappel, Burcon's interim CEO and Chairman of the board, adding, "Merit reached a significant milestone
Vancouver, British Columbia--(Newsfile Corp. - September 6, 2022) - Burcon NutraScience Corporation (TSX:BU) (NASDAQ:BRCN) ("Burcon" or the "Company"), a global technology leader in the development of plant-based proteins for foods and beverages, today issued a letter to shareholders from its Interim CEO and Chairman of the Board, Peter H. Kappel.Dear Fellow Shareholders,This past Friday we announced the resignation of our Auditor of the past 21 years, PricewaterhouseCoopers LLP ("PwC"). This must have come as a surprise to you, as it did us when we were informed by PwC their intention to resign. What was particularly agonizing for us was their insistence on the immediacy of carrying throu
Vancouver, British Columbia--(Newsfile Corp. - September 2, 2022) - Burcon NutraScience Corporation (TSX:BU) (NASDAQ:BRCN) ("Burcon" or the "Company"), a global technology leader in the development of plant-based proteins for foods and beverages, today announced the resignation of its auditors, PricewaterhouseCoopers LLP ("PwC"), effective September 1, 2022 and that it is postponing its annual meeting of shareholders (the "AGM"), which was to be held on September 14, 2022.PwC has confirmed that there have been no "reportable events", "disagreements" or "unresolved issues" (as such terms are defined in National Instrument 51-102 - Continuous Disclosure Obligations). Due to the inopportune tim
Vancouver, British Columbia--(Newsfile Corp. - March 1, 2022) - Burcon NutraScience Corporation (TSX:BU) (NASDAQ:BRCN) ("Burcon or the "Company"), a global technology leader in the development of plant-based proteins for foods and beverages, is pleased to announce that Peter H. Kappel, Chairman of Burcon's board of directors, will assume the role of interim Chief Executive Officer ("CEO"), with immediate effect, until a successor is appointed by the Company's board of directors.Mr. Kappel is a former investment banker who served in senior roles at Nomura, Dresdner Kleinwort Wasserstein, Calyon and DVB Bank in London. He brings extensive experience in strategic and business management as well
Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility. IVERIC bio, Inc. (NASDAQ:ISEE) rose 66.3% to close at $15.70 on Tuesday after the company announced positive data from the second Phase 3 trial of Zimura (avacincaptad pegol) for geographic atrophy (GA). HyreCar Inc. (NASDAQ:HYRE) climbed 58.1% to close at $1.27 on Tuesday after the company announced it has received a $100 million revolving line of credit from a premier global investment bank and Medalist Partners. Spero Therapeutics, Inc. (NASDAQ:SPRO) gained 55.5% to close at $1.13. Spero Therapeutics received minutes from a recent Type A meeting wi
Gainers HyreCar Inc. (NASDAQ:HYRE) jumped 60% to $1.2680 after the company announced it has received a $100 million revolving line of credit from a premier global investment bank and Medalist Partners. ChannelAdvisor Corporation (NYSE:ECOM) shares climbed 54.9% to $22.77 after the company announced it will be acquired by CommerceHub for $23.10 per share IVERIC bio, Inc. (NASDAQ:ISEE) gained 41.4% to $13.35 after the company announced positive data from the second Phase 3 trial of Zimura (avacincaptad pegol) for geographic atrophy (GA). Nutex Health, Inc. (NASDAQ:NUTX) rose 39% to $3.33. Nutex Health recently reported Q2 earnings results. Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:
Gainers First Wave BioPharma, Inc. (NASDAQ:FWBI) shares rose 39.6% to $4.44 in pre-market trading after gaining 7% on Friday. Organovo Holdings, Inc. (NASDAQ:ONVO) rose 25.1% to $2.89 in pre-market trading. Tian Ruixiang Holdings Ltd (NASDAQ:TIRX) shares rose 24% to $0.85 in pre-market trading after declining around 5% on Friday. Rubius Therapeutics, Inc. (NASDAQ:RUBY) rose 16.7% to $1.08 in pre-market trading after climbing over 23% on Friday. CytomX Therapeutics, Inc. (NASDAQ:CTMX) rose 15.1% to $1.68 in pre-market trading. CytomX Therapeutics, last month, posted a Q2 loss of $0.37 per share. GlycoMimetics, Inc. (NASDAQ:GLYC) rose 15% to $0.85 in pre-market trading. The company